| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6099951 | Journal of Crohn's and Colitis | 2013 | 8 Pages |
Abstract
Combination therapy with IFX plus AZA appears to be a cost-effective treatment for drug-refractory CD when compared with IFX monotherapy. Furthermore, the additional lymphoma risk of combination therapy has little significance on its cost-effectiveness.
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Shota Saito, Utako Shimizu, Zhang Nan, Nozomu Mandai, Junji Yokoyama, Kenshi Terajima, Kouhei Akazawa,